MiMedx Net Worth
MiMedx Net Worth Breakdown | MDXG |
MiMedx Net Worth Analysis
MiMedx's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including MiMedx's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of MiMedx's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform MiMedx's net worth analysis. One common approach is to calculate MiMedx's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares MiMedx's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing MiMedx's net worth. This approach calculates the present value of MiMedx's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of MiMedx's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate MiMedx's net worth. This involves comparing MiMedx's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into MiMedx's net worth relative to its peers.
Enterprise Value |
|
To determine if MiMedx is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MiMedx's net worth research are outlined below:
| MiMedx Group appears to be risky and price may revert if volatility continues | |
| MiMedx Group is unlikely to experience financial distress in the next 2 years | |
| About 68.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: How Much Upside is Left in MiMedx Wall Street Analysts Think 37.12 |
MiMedx Quarterly Good Will |
|
MiMedx uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MiMedx Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MiMedx's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know MiMedx's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MiMedx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MiMedx Group backward and forwards among themselves. MiMedx's institutional investor refers to the entity that pools money to purchase MiMedx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 1.5 M | Royal Bank Of Canada | 2024-06-30 | 1.5 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.1 M | Royce & Associates, Lp | 2024-09-30 | 972.9 K | Richmond Brothers Inc | 2024-06-30 | 917.3 K | Federated Hermes Inc | 2024-09-30 | 906.8 K | Arrowstreet Capital Limited Partnership | 2024-06-30 | 903.1 K | Millennium Management Llc | 2024-06-30 | 889.4 K | Essex Woodlands Health Ventures | 2024-09-30 | 28.2 M | Blackrock Inc | 2024-06-30 | 9.3 M |
Follow MiMedx's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.33 B.Market Cap |
|
Project MiMedx's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.31 | 0.33 | |
| Return On Capital Employed | 0.19 | 0.20 | |
| Return On Assets | 0.28 | 0.30 | |
| Return On Equity | 0.47 | 0.45 |
When accessing MiMedx's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures MiMedx's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MiMedx's profitability and make more informed investment decisions.
Evaluate MiMedx's management efficiency
MiMedx Group has return on total asset (ROA) of 0.1838 % which means that it generated a profit of $0.1838 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6247 %, meaning that it created $0.6247 on every $100 dollars invested by stockholders. MiMedx's management efficiency ratios could be used to measure how well MiMedx manages its routine affairs as well as how well it operates its assets and liabilities. At this time, MiMedx's Return On Assets are most likely to increase slightly in the upcoming years. At this time, MiMedx's Total Current Assets are most likely to increase significantly in the upcoming years. The MiMedx's current Intangible Assets is estimated to increase to about 9.5 M, while Other Current Assets are projected to decrease to roughly 4.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.23 | 1.29 | |
| Tangible Book Value Per Share | 1.01 | 1.06 | |
| Enterprise Value Over EBITDA | 24.38 | 25.60 | |
| Price Book Value Ratio | 7.16 | 6.80 | |
| Enterprise Value Multiple | 24.38 | 25.60 | |
| Price Fair Value | 7.16 | 6.80 | |
| Enterprise Value | 987.8 M | 1 B |
The management strategies employed by MiMedx's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Enterprise Value Revenue 3.6801 | Revenue 342.8 M | Quarterly Revenue Growth 0.029 | Revenue Per Share 2.447 | Return On Equity 0.6247 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MiMedx insiders, such as employees or executives, is commonly permitted as long as it does not rely on MiMedx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MiMedx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MiMedx Corporate Filings
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 7th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
10Q | 30th of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
MiMedx Earnings per Share Projection vs Actual
MiMedx Corporate Management
| Matthew Notarianni | Head Relations | Profile | |
| Todd Newton | Interim Director | Profile | |
| William Phelan | VP Officer | Profile | |
| Kim Moller | Chief Officer | Profile | |
| William IV | General Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.1) | Earnings Share 0.57 | Revenue Per Share 2.447 | Quarterly Revenue Growth 0.029 | Return On Assets 0.1838 |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.